Premium
Targeting of cancer energy metabolism
Author(s) -
RodríguezEnríquez Sara,
MarínHernández Alvaro,
GallardoPérez Juan Carlos,
CarreñoFuentes Liliana,
MorenoSánchez Rafael
Publication year - 2009
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.200700470
Subject(s) - energy metabolism , cancer , computational biology , metabolism , biology , bioinformatics , genetics , biochemistry , endocrinology
The main purpose of this review is to update and analyze the effect of several antineoplastic drugs (adriamycin, apoptodilin, casiopeinas, cisplatin, clotrimazole, cyclophosphamide, ditercalinium, NSAIDs, tamoxifen, taxol, 6‐mercaptopurine, and α‐tocopheryl succinate) and energy metabolism inhibitors (2‐DOG, gossypol, delocalized lipophilic cations, and uncouplers) on tumor development and progression. The possibility that these antineoplastic drugs currently used in in vitro cancer models, in chemo‐therapy, or under study in phase I to III clinical trials induce tumor cellular death by altering also metabolite concentration ( i.e ., ATP), enzyme activities, and/or energy metabolism fluxes is assessed. It is proposed that the use of energy metabolic therapy, as an alternative or complementary strategy, might be a promising novel approach in the treatment of cancer.